ABEO - ABEONA THERAPEUTICS INC.
IEX Last Trade
5.705
0.045 0.789%
Share volume: 2,866
Last Updated: Thu 26 Dec 2024 08:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$5.66
0.05
0.80%
Fundamental analysis
6%
Profitability
0%
Dept financing
6%
Liquidity
46%
Performance
2%
Performance
5 Days
-0.18%
1 Month
-5.80%
3 Months
-4.22%
6 Months
38.88%
1 Year
11.59%
2 Year
135.68%
Key data
Stock price
$5.70
DAY RANGE
$5.60 - $5.70
52 WEEK RANGE
$3.28 - $9.01
52 WEEK CHANGE
$10.51
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Vishwas Seshadri
Region: US
Website: abeonatherapeutics.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: abeonatherapeutics.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Abeona Therapeutics Inc. develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A.
Recent news